Today: 7 February 2026
Subscribe
Browse Category

NYSE:MRK News 31 December 2025 - 12 January 2026

Tempus AI stock jumps in premarket after $1.27 billion revenue preview, contract value tops $1.1 billion

Tempus AI stock jumps in premarket after $1.27 billion revenue preview, contract value tops $1.1 billion

Tempus AI shares rose about 11% in premarket trading Monday after the company reported preliminary 2025 revenue of $1.27 billion, up 83% year-on-year, and record contract value exceeding $1.1 billion. The company cited strong growth in both Diagnostics and Data segments, with over 70 new data agreements signed in 2025. Tempus noted the results are unaudited and subject to change.
12 January 2026
·······
Merck (MRK) stock week ahead: $30 billion Revolution talks and JPMorgan catalysts to watch

Merck (MRK) stock week ahead: $30 billion Revolution talks and JPMorgan catalysts to watch

Merck shares fell 0.4% to $110.53 Friday as reports surfaced of talks to buy Revolution Medicines in a deal valued at $28 billion to $32 billion. Revolution shares jumped 10.7% on the speculation. The Wall Street Journal and Financial Times said the deal would be among the largest pre-commercial biotech acquisitions. Investors await updates at the JPMorgan Healthcare Conference on Monday.
11 January 2026
···
Merck stock: $32 billion Revolution Medicines talks and vaccine-policy shift set up a busy week for MRK

Merck stock: $32 billion Revolution Medicines talks and vaccine-policy shift set up a busy week for MRK

Merck shares fell 0.4% to $110.53 Friday after reports it is in talks to acquire Revolution Medicines for $28–32 billion. Revolution shares jumped in after-hours trading. The Financial Times said negotiations are ongoing, with no final deal yet. Investors are watching Merck’s appearance at the J.P. Morgan Healthcare Conference on Jan. 12.
10 January 2026
··
Cisco (CSCO) stock in focus as Supreme Court takes up Falun Gong lawsuit appeal

Cisco (CSCO) stock in focus as Supreme Court takes up Falun Gong lawsuit appeal

Cisco Systems shares slipped 0.1% to $73.88 after the U.S. Supreme Court agreed to hear its appeal in a lawsuit alleging the company aided China’s surveillance of Falun Gong practitioners. The case centers on whether U.S. law allows “aiding and abetting” claims against corporations for overseas abuses. Cisco denies wrongdoing and welcomed the court’s review. The company will report quarterly earnings on Feb. 11.
10 January 2026
·····
Merck stock dips after $32 billion Revolution Medicines talks report, with Gardasil and Keytruda in focus

Merck stock dips after $32 billion Revolution Medicines talks report, with Gardasil and Keytruda in focus

Merck shares fell 0.4% to $110.53 after reports it is in talks to acquire Revolution Medicines for up to $32 billion. The company faces new scrutiny over its Gardasil and RotaTeq vaccines after U.S. policy changes, with analysts estimating a $2 billion annual revenue impact. Wolfe Research upgraded Merck, citing progress on a subcutaneous version of Keytruda.
10 January 2026
····
Merck buyout chatter jolts Revolution Medicines (RVMD) stock after FDA breakthrough nod

Merck buyout chatter jolts Revolution Medicines (RVMD) stock after FDA breakthrough nod

Revolution Medicines shares surged 10.7% to $118.64 in after-hours trading Friday after the Financial Times reported Merck is in advanced talks to acquire the company for $28 billion to $32 billion. The move follows the FDA granting Breakthrough Therapy designation to Revolution’s zoldonrasib for KRAS G12D-mutated lung cancer. Investors await Revolution’s Jan. 12 conference appearance for updates.
9 January 2026
··
Merck (MRK) stock today: $32 billion Revolution talks and CDC vaccine shift put Feb. 3 in play

Merck (MRK) stock today: $32 billion Revolution talks and CDC vaccine shift put Feb. 3 in play

Merck shares rose 0.4% to $111.41 Friday after a report said it is in talks to buy Revolution Medicines for $28–32 billion. Revolution shares jumped 16% in extended trading. Merck just completed a $221.50-per-share tender offer for Cidara Therapeutics and said the deal will raise 2026 R&D expense by $9 billion. Analysts warned U.S. vaccine policy changes could cut Merck revenue by $2 billion annually.
9 January 2026
···
Merck stock climbs on Wolfe upgrade as Cidara deal closes and Gardasil questions linger

Merck stock climbs on Wolfe upgrade as Cidara deal closes and Gardasil questions linger

Merck shares rose 1.5% to $110.20 after Wolfe Research upgraded the stock and set a $135 price target. Merck completed its $221.50-per-share tender offer for Cidara and flagged a $9 billion R&D charge for 2026. Investors watched fallout from a U.S. shift to a single-dose HPV vaccine recommendation ahead of Merck’s Feb. 3 results.
8 January 2026
····
Merck (MRK) stock slips after-hours as CDC backs one-dose HPV shot; Cidara deal closes

Merck (MRK) stock slips after-hours as CDC backs one-dose HPV shot; Cidara deal closes

Merck shares slipped 0.2% in after-hours trading after U.S. health officials cut HPV vaccine guidance to one dose, raising concerns over Gardasil sales. Analysts warned the change could reduce 2026 Gardasil revenue by up to $630 million. Merck also completed its $9.2 billion Cidara acquisition and set Feb. 3 for quarterly results.
8 January 2026
····
Merck stock slips after Cidara tender offer; $9 billion R&D hit and HPV schedule shift in focus

Merck stock slips after Cidara tender offer; $9 billion R&D hit and HPV schedule shift in focus

Merck shares slipped 0.3% to $108.59 after it completed its tender offer for Cidara Therapeutics and expects to finalize the $9.2 billion acquisition later Wednesday. The deal will add about $9 billion to 2026 R&D expenses and reduce earnings per share by 30 cents in the first year. Merck also began a Phase 3 lung-cancer trial of calderasib with Keytruda QLEX. U.S. officials updated HPV and rotavirus vaccine guidance this week.
7 January 2026
·····
Merck stock hits 52-week high as vaccine policy shift and JPM conference loom

Merck stock hits 52-week high as vaccine policy shift and JPM conference loom

Merck shares rose 1.1% to $108.60 Tuesday, hitting a 52-week high of $110.16 amid investor focus on U.S. vaccine schedule changes and upcoming CEO remarks at the J.P. Morgan Healthcare Conference Jan. 12. The company’s Gardasil HPV vaccine faces uncertainty after the CDC shifted to a single-dose recommendation, while an FDA decision on Keytruda in ovarian cancer is expected Feb. 20.
6 January 2026
··
Merck stock starts 2026 higher as Cidara tender-offer deadline hits next week

Merck stock starts 2026 higher as Cidara tender-offer deadline hits next week

NEW YORK, Jan 3, 2026, 15:08 ET — Market closed Merck & Co. (MRK) shares ended Friday up about 1.2% at $106.45. Nasdaq said the cash tender offer for Cidara Therapeutics is scheduled to expire one minute after 11:59 p.m. ET on Jan. 6, with the merger tentatively slated to close before the market opens Jan. 7. The exchange said Cidara shares would be halted after the after-hours session on Jan. 6 and suspended Jan. 8 if the deal closes as planned. NASDAQ Trader That timetable matters now because it gives Merck investors a near-term corporate catalyst at the start
3 January 2026
···
Johnson & Johnson stock ticks up after $1.30 dividend; earnings next on the radar

Johnson & Johnson stock ticks up after $1.30 dividend; earnings next on the radar

NEW YORK, Jan 2, 2026, 20:13 ET — Market closed Johnson & Johnson shares ended Friday up 0.19% at $207.35 after the healthcare company said its board declared a $1.30-per-share cash dividend for the first quarter of 2026. Yahoo Finance The timing matters because investors entered 2026 with markets trying to stabilize after a late-December stretch that failed to deliver the usual year-end “Santa Claus” bounce. Wall Street’s focus is shifting back to interest-rate expectations and the next round of economic data. Reuters For income-focused investors, dividends can act as a buffer in volatile tape because they provide a cash
3 January 2026
·····
Merck (MRK) stock slips into 2026 as New Year holiday shuts U.S. markets — what investors watch next

Merck (MRK) stock slips into 2026 as New Year holiday shuts U.S. markets — what investors watch next

NEW YORK, January 1, 2026, 14:30 ET — Market closed Merck & Co.’s stock ended the year’s final trading session lower and was little changed in after-hours trading — the session after the 4 p.m. close — with U.S. markets shut on Thursday for New Year’s Day. The shares closed Dec. 31 down 0.75% at $105.26 and last traded at $105.40 after hours. Investing.com+1 The holiday pause comes after Wall Street slid in thin year-end trade on Wednesday, leaving investors to reset positions for 2026 without a fresh U.S. equity session on the holiday. The S&P 500 fell 0.74% on
1 January 2026
·
Merck stock dips after hours as 2025 ends; MRK investors shift focus to Feb. 3 earnings

Merck stock dips after hours as 2025 ends; MRK investors shift focus to Feb. 3 earnings

NEW YORK, December 31, 2025, 19:34 ET — After-hours Merck & Co (MRK) shares slipped about 0.7% to $105.26 in after-hours trading on Wednesday, the electronic session after the 4 p.m. close. The stock traded between $104.97 and $106.08 and logged about 7.6 million shares in volume. The late move capped a holiday-shortened week when lighter volume can amplify small swings, especially after the year’s final closing bell. For Merck holders, the calendar matters as much as the tape. Investors are watching how the drugmaker sustains growth beyond Keytruda, its blockbuster cancer drug, as the franchise heads toward a patent
1 January 2026
···
Merck (MRK) stock slips at the close, then steadies after hours as year-end trading thins

Merck (MRK) stock slips at the close, then steadies after hours as year-end trading thins

NEW YORK, December 30, 2025, 19:42 ET — After-hours Merck & Company, Inc. (MRK) shares fell 0.53% to $106.06 at the close on Tuesday and were up about 0.1% in after-hours trading at $106.17. The stock has traded between $73.31 and $107.59 over the past 52 weeks. Investing.com The muted move matters now because liquidity typically thins into year-end, which can exaggerate small price swings even in defensive healthcare names. Merck has scheduled its fourth-quarter earnings call for Feb. 3, putting its 2026 outlook in focus as investors reset positions for the new year. Merck.com Wall Street’s main indexes closed
31 December 2025
·
1 2 3 4 5

Stock Market Today

Home Depot stock price: jobs, inflation and a Feb. 24 earnings test loom

Home Depot stock price: jobs, inflation and a Feb. 24 earnings test loom

7 February 2026
Home Depot shares rose 0.7% to $385.15 Friday, trading between $379.10 and $386.37. Investors await a delayed U.S. jobs report Wednesday and CPI data Friday, both postponed by a brief government shutdown. Home Depot reports fourth-quarter earnings Feb. 24. The Dow closed above 50,000 for the first time.
JPMorgan stock price jumps 4% into weekend as Wall Street braces for a busy data week

JPMorgan stock price jumps 4% into weekend as Wall Street braces for a busy data week

7 February 2026
JPMorgan shares rose 3.95% to $322.40 Friday, outpacing other major banks as U.S. stocks rallied and the Dow closed above 50,000 for the first time. The bank recently completed a $3 billion subordinated notes offering. Investors are watching for delayed U.S. jobs data and inflation figures next week, ahead of JPMorgan’s Feb. 23 company update.
AbbVie stock price: ABBV ends week near $223 after earnings swing — what to watch next

AbbVie stock price: ABBV ends week near $223 after earnings swing — what to watch next

7 February 2026
AbbVie shares rose 2% to $223.43 Friday, capping a volatile week marked by earnings and drug sales scrutiny. Moody’s upgraded AbbVie’s credit rating to A2, citing strong performance in immunology and neuroscience. Investors remain focused on Skyrizi and Rinvoq growth amid rising competition and recent regulatory filings. Trading volume stayed below average, with the stock still 9% off its 52-week high.
SK hynix stock price slips into Monday after S&P upgrade, tech selloff

SK hynix stock price slips into Monday after S&P upgrade, tech selloff

7 February 2026
SK hynix shares closed at 839,000 won, down 0.36% Friday and 8% for the week, as tech stocks retreated across Asia. S&P Global Ratings upgraded the chipmaker to “BBB+” with a positive outlook, citing strong HBM sales. The KOSPI fell 1.4% Friday, ending a six-week winning streak. Traders await Monday’s Seoul open for signs of further tech weakness.
Go toTop